Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
ORLANDO — In this video from the American Academy of Ophthalmology meeting, Stephen J. Kim, MD, discusses the controversy surrounding FDA-approved treatments for geographic atrophy.
Two treatments are commercially available, but Kim, professor of ophthalmology at Vanderbilt Eye Institute, said the drugs are invasive and expensive, have side effects, and “don’t provide any meaningful visual function benefit.”
“They have some ability to modestly slow the rate of progression of the disease, but it hasn’t translated into any meaningful visual benefit that the patient can sense,” he said.